Shanghai Henlius Biotech, Inc. has issued the proxy form for its 2026 First Extraordinary General Meeting (EGM), to be convened on 23 November 2026 at 2:00 p.m. in the company’s Conference Room, 10th Floor, B8 Building, No. 188 Yizhou Road, Xuhui District, Shanghai.
Key items to be tabled for shareholder approval are:
1. Revision of Annual Cap for HLX01 Collaboration • Shareholders will vote on increasing the annual cap governing collaboration arrangements under the HLX01 Agreement. • Directors will be authorised to execute all documents and actions necessary to implement the revised cap.
2. Board Composition Changes • Appointment of Mr. Zhi Huang as a non-executive director. • Appointment of Dr. Huajun Chen as an independent non-executive director.
Shareholders holding both unlisted shares and H shares may attend in person or appoint proxies. Completed proxy forms, together with any relevant power of attorney, must be lodged with the company’s Board Secretary Office in Shanghai (for unlisted shares) or with Computershare Hong Kong Investor Services Limited (for H shares) no later than 2:00 p.m. on 22 November 2026 (Beijing time).
Only the holder whose name appears first on the register of members for any jointly-held share will be entitled to vote if multiple joint holders are present. Attendance in person will supersede any lodged proxy.
The company emphasises that the proxy process and personal data collected will be used solely for arranging the EGM and related voting procedures, in line with applicable privacy regulations.
Comments